FDA Issues Losartan Blood Pressure Medication Recall Over Cancer Risk

Two more blood pressure medications recalled over cancer concerns

Several blood pressure medications have been recalled within the last few months, and two more have recently been added to the list. 

» RELATED: Yet another blood pressure medication recalled over cancer risk

Teva Pharmaceuticals has voluntarily recalled the Amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide combination tablets, the U.S. Food and Drug Administration announced.

According to the press release, the drugs contain too much N-nitroso-diethylamine (NDEA), a chemical manufactured in Mylan, India. The key ingredient, typically found in certain foods, drinking water and air pollution, has been classified as a human carcinogen by the International Agency for Research on Cancer. 

» RELATED: Half of US adults now have high blood pressure, based on new guidelines

Teva noted it has not received any reports of illness, but it has asked its retailers to stop distributing the products and to return them immediately. 

Patients on the medications are advised to continue taking the tablets and to contact their doctor for advice for alternate treatments. The company said,  “the risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any comparable alternative treatment.”

The agency recently recalled three other blood pressure medications due to cancer concerns, and another was recalled for mislabeling

Read the full FDA announcement at FDA.gov.

Support real journalism. Support local journalism. Subscribe to The Atlanta Journal-Constitution today. See offers.

Your subscription to the Atlanta Journal-Constitution funds in-depth reporting and investigations that keep you informed. Thank you for supporting real journalism.

X